Clinical Trials on Edematous Fibrosclerotic Panniculopathy in Hong Kong

Total 46 results

Endo Pharmaceuticals

Completed

Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)

Cellulite | Edematous Fibrosclerotic Panniculopathy

United States
Endo Pharmaceuticals

Completed

Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women (RELEASE-1)

Edematous Fibrosclerotic Panniculopathy (Cellulite)

United States
Hong Kong Baptist University

Unknown

Ganoderma Tea on Eczema Patient

Eczema

Hong Kong
Chinese University of Hong Kong

Completed

GB-EZ-SIM03 Probiotics Study for Childhood Eczema

Eczema

Hong Kong
Prof. HON Kam Lun Ellis

Completed

Effect of a Topical Spray on Itch Relief in Moderate-to-severe Childhood Eczema

Eczema

Hong Kong
Chinese University of Hong Kong

Recruiting

A Pilot Study of Efficacy and Safety of SIM05 in Adults With Atopic Eczema

Atopic Eczema

Hong Kong
Chinese University of Hong Kong

Active, not recruiting

Evaluate the Efficacy of Using Modified Qing-Ying Decoction in Atopic Dermatitis Children

Atopic Dermatitis

Hong Kong
Chinese University of Hong Kong

Recruiting

Modified Huang-Lian-Jie-Du Decoction (MHLJDD) for Atopic Dermatitis in Children

Atopic Dermatitis

Hong Kong
The University of Hong Kong

Recruiting

Integrative Body-Mind-Spirit Intervention for Families With Children Suffering From Eczema

Eczema | Dermatitis, Atopic

Hong Kong
The University of Hong Kong
The Hong Kong Polytechnic University

Active, not recruiting

Epidemiological Survey and Genetic Analysis of AD Patients in Hong Kong

Eczema | Atopic Dermatitis | Genetic Skin Disease

Hong Kong
Chinese University of Hong Kong
Tuen Mun Hospital

Recruiting

Acceptance and Commitment Therapy-based Eczema Management Programme (ACTeczema)

Eczema

Hong Kong
Northwestern University

Completed

Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index

Psoriasis | Atopic Dermatitis

Chile, United States, Netherlands, Canada, Hong Kong, Italy
Amytrx Therapeutics, Inc.
Amarex Clinical Research

Completed

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Principia Biopharma, a Sanofi Company

Completed

Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Edesa Biotech Inc.
JSS Medical Research Inc.

Active, not recruiting

Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis

Allergic Contact Dermatitis

United States, Canada
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (SOLO 2)

Dermatitis, Atopic

United States, France, Poland, United Kingdom, Germany, Hong Kong, Canada, Korea, Republic of, Italy, Lithuania, Sweden
Amgen

Recruiting

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD (ROCKET-Outpost)

Atopic Dermatitis

United States
Amgen

Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit)

Atopic Dermatitis

Korea, Republic of, Australia, United States, United Kingdom, Hong Kong, Turkey, Brazil, Argentina, Canada
Regeneron Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis

Hypersensitivity, Immediate | Dermatitis, Atopic | Moderate-to-Severe Atopic Dermatitis | Dermatitis, Dermatitis Atopic | Eczema, Skin Diseases, Skin | Diseases Genetic, Genetic | Diseases Inborn, Skin | Disease, Eczematous Skin | Hypersensitivity, Immune System Diseases

United States, Canada
ASLAN Pharmaceuticals

Recruiting

Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab

Atopic Dermatitis

United States, Canada
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

Eczema, Atopic | Atopic Disorders

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)

Atopic Dermatitis

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL) (Liberty AD)

Dermatitis, Atopic

United States, Germany, Poland, United Kingdom
Incyte Corporation

Recruiting

The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance. (MORPHEUS)

Atopic Dermatitis

United States
Regeneron Pharmaceuticals
Sanofi

Terminated

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

United States, Korea, Republic of, Belgium, Czechia, Germany, Poland, Spain
Glenmark Pharmaceuticals Ltd. India

Completed

To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)

Atopic Dermatitis

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

Dermatitis, Atopic

United States, Germany, Poland, Canada, Czechia, United Kingdom
Pfizer

Available

Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

Taiwan, United States, Australia, Austria, Belgium, Canada, Greece, Mexico, Netherlands, Russian Federation, Spain, Switzerland
Galderma R&D

Completed

A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab

Dermatitis, Atopic

United States
Pfizer

Completed

Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

Atopic Dermatitis

Germany, United States, Canada, Denmark, Hungary, Australia, Latvia, Poland, Bulgaria, Japan
Dermavant Sciences GmbH

Completed

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)

Atopic Dermatitis

United States, Canada
Vanda Pharmaceuticals

Completed

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)

Atopic Dermatitis

United States
AOBiome LLC
bioRASI, LLC

Completed

B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis

Atopic Dermatitis

United States
AbbVie

Enrolling by invitation

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (AD Up)

Atopic Dermatitis

United States, Australia, Austria, Belgium, Canada, China, Czechia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Puerto Rico, Slovakia, Spain, Sweden, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

Atopic Dermatitis

United States, Canada, Czechia, Germany, Hungary, Poland, United Kingdom
Amgen

Active, not recruiting

A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) (ROCKET-VOYAGER)

Atopic Dermatitis | Moderate-to-severe Atopic Dermatitis

United States, Canada
Regeneron Pharmaceuticals
Sanofi

Completed

Open-label Study of Dupilumab in Patients With Atopic Dermatitis

Atopic Dermatitis

Hungary, Netherlands, Spain, United Kingdom, United States, Australia, Austria, Belgium, Bulgaria, Canada, China, Czechia, Denmark, Estonia, Finland, France, Germany, Ireland, Italy, Japan, Korea, Republic of, Lithuania, New Zealand, ... and more
Kymab Limited
Sanofi

Completed

Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study (STREAM-AD)

Eczema | Atopic Dermatitis

United States, Australia, Bulgaria, Canada, Czechia, Germany, Hungary, Japan, Poland, Spain, Taiwan, United Kingdom
Dermavant Sciences, Inc.

Completed

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Pfizer

Completed

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Atopic Dermatitis

Spain, Taiwan, United States, Korea, Republic of, Poland, Canada, Australia, Hungary, Germany, Latvia, Finland, Chile, Bulgaria, Slovakia, Italy
Pfizer

Completed

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

Skin Diseases | Immune System Diseases | Hypersensitivity | Hypersensitivity, Immediate | Genetic Diseases, Inborn | Skin Diseases, Genetic | Dermatitis | Eczema | Skin Diseases, Eczematous | Dermatitis, Atopic

United States, Spain, Taiwan, Germany, Canada, China, Poland, Belgium, Serbia, Brazil, Russian Federation, Israel, Latvia, Italy, Romania, Mexico, Argentina, Bulgaria, Chile, Netherlands, Slovakia
Pfizer

Completed

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy (JADE Compare)

Skin Diseases | Immune System Diseases | Hypersensitivity | Hypersensitivity, Immediate | Genetic Diseases, Inborn | Skin Diseases, Genetic | Dermatitis | Eczema | Skin Diseases, Eczematous | Dermatitis, Atopic

Spain, Taiwan, United States, Australia, Poland, Germany, Hungary, Bulgaria, Czechia, Japan, Korea, Republic of, Latvia, Canada, United Kingdom, Mexico, Chile, Slovakia, Italy
Amgen

Recruiting

A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) (ROCKET-Ignite)

Atopic Dermatitis

Japan, Korea, Republic of, United States, Taiwan, Spain, Germany, Croatia, China, Greece, Italy, Czechia, Brazil, Poland, Portugal, Slovakia, Argentina, Canada, Puerto Rico, Hungary, Latvia, Netherlands
AbbVie

Active, not recruiting

A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

Atopic Dermatitis

United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Korea, Republic of, Netherlands, New Zealand, Portugal, Singapore, Spain, Taiwan, United Kingdom
Amgen

Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

Atopic Dermatitis

United States, Japan, Korea, Republic of, Australia, Taiwan, Spain, Switzerland, Germany, Austria, Denmark, Netherlands, Hungary, Czechia, Brazil, France, Poland, Portugal, Argentina, Italy, Slovenia, Singapore, Canada, Estonia, Malaysia and more
Pfizer

Active, not recruiting

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

Dermatitis, Atopic

China, United States, Spain, Taiwan, Germany, Australia, Canada, Hungary, Korea, Republic of, Poland, Serbia, Bulgaria, Czechia, Japan, Latvia, United Kingdom, Belgium, Israel, Italy, Finland, Mexico, Romania, Slovakia, Argentina, Brazil, Chil... and more

3

Subscribe